ChemDiv chemistry of cures

ChemDiv - Dendreon Partnership

Dendreon Corporation is a Seattle based company dedicated to discovery, development and commercialization of novel therapeutics to fight cancer. Dendreon was looking for a partner to support its TRPM8 (also known as TRPP8) inhibitor discovery program, which was identified through in-house efforts. Having lots of in-house expertise in and knowledge of immunotherapeutics, the company lacked sufficient internal resources in small-molecule drug discovery to rapidly and efficiently move the program towards a series of critical milestones put in place by Dendreon. This triggered Denderon's quest to find a reliable and experienced partner in small-molecule drug discovery, specifically with an excellent track record in medicinal chemistry. Dendreon had already worked with ChemDiv before on a number of smaller-scale chemistry projects and its decision to approach ChemDiv with a larger and therefore more challenging program was a logical step in building up relationships between two organizations. ChemDiv's expertise in custom chemistry and lead optimization solutions as well as stellar reputation in the industry has sealed the deal.

In the course of a few years, a group of dedicated ChemDiv scientists (chemists and biologists) worked hand-in-hand with Dendreon's team to advance the program to the clinical candidate stage. Looking back at major stepping stones of this collaboration's success, one would recognize the highest level of commitment of both teams to thrive through trust, resourcefulness, dedication, communication and highest level of professionalism. Currently, the lead molecule, D3263, is in a Phase 1 clinical trial for clinical evaluation in cancer patients.

About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. Dendreon has its headquarters in Seattle, Washington.